stockrow
Saturday 7 November 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
- EPS
- −123.3%
- Free cash flow
- +34.3%
Quarter to June 2026, against a year earlier
0.90
0.01
−1.10%
Follow NBP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | 2 | 8 | 4 | 236 | 14 | (32) | 1 | — | — | 19 | (15.3%) | 1 | — | — | — | |
| Gross margin, % | — | 0.00 | 0.00 | 100.00 | 100.00 | 47.25 | 112.29 | 100.00 | — | — | 31.10 | +100.0 pt | ||||||
| EBT | — | (44) | (61) | (209) | 74 | (366) | (363) | (82) | (50) | (88) | (40) | +9.1% | ||||||
| EBT margin, % | — | (2,580.85) | (745.82) | (4,840.10) | 31.32 | (2,652.32) | 1,131.32 | (13,009.02) | 0.00 | 0.00 | 0.00 | +2,580.9 pt | ||||||
| Net income | — | 0 | 0 | (209) | 72 | (366) | (364) | (82) | (50) | (88) | (53) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.03 | 0.14 | 1.34 | 4.05 | 0.18 | (0.39) | 0.01 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (1.05) | (64.99) | 1.24 | (4.82) | (4.24) | (2.50) | (0.27) | (0.48) | (0.49) | (10.6%) | ||||||
| Cash flow | — | (0.64) | (0.73) | (38.85) | 1.14 | (2.01) | (1.94) | (0.87) | (0.65) | (0.22) | 0.00 | (12.8%) | ||||||
| Capex | — | 0.00 | 0.00 | (0.55) | (0.02) | (0.06) | (0.08) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (0.64) | (0.73) | (39.40) | 1.12 | (2.07) | (2.02) | (0.88) | (0.65) | (0.21) | 0.00 | (12.8%) | ||||||
| Book value | — | (0.79) | (2.39) | 59.43 | 14.78 | 9.42 | 5.11 | 2.91 | 2.48 | 2.41 | 0.00 | n/m | ||||||
| Shares, m | — | 58 | 58 | 3 | 58 | 76 | 83 | 83 | 81 | 96 | 81 | +6.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 | |||||
| P/S | — | 6.19 | 6.19 | 6.19 | 16.47 | 15.05 | 1.37 | 9.73 | — | — | 3.79 | 8.7 | ||||||
| P/B | — | 0.23 | 0.23 | 0.23 | 4.52 | 5.19 | 0.83 | 0.78 | — | — | 0.37 | 1.7 | ||||||
| EV/Sales | — | (16.57) | (16.57) | (16.57) | 13.42 | 12.39 | (0.60) | (5.58) | — | — | (5.33) | (4.3) | ||||||
| EV/FCF | — | 0.00 | 0.00 | 0.00 | (19.50) | (12.69) | 0.33 | 0.25 | — | — | 1.12 | (4.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (37) | (42) | (125) | 66 | (153) | (160) | (73) | (53) | (21) | (92) | (7.2%) | |||||
| Capex | — | (3) | (2) | (2) | (1) | (5) | (7) | 0 | 0 | 0 | (1) | n/m | ||||||
| Free cash flow | — | (37) | (42) | (126) | 65 | (157) | (167) | (73) | (53) | (21) | (93) | (7.2%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 76 | 246 | 148 | 731 | 652 | 416 | 272 | 168 | 191 | 172 | +12.1% | |||||
| Net debt | — | 38 | 170 | (159) | (733) | (666) | (511) | (312) | (173) | (211) | (191) | n/m | ||||||
| Shareholders’ equity | — | (46) | (139) | 191 | 862 | 715 | 422 | 243 | 201 | 231 | 201 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (17.53) | 0.00 | (170.93) | 11.83 | (39.56) | (49.47) | (43.30) | (7.64) | (19.56) | 0.00 | (2.0) pt | |||||
| ROIC | — | 0.00 | 0.00 | (415.21) | 11.51 | (413.03) | 0.00 | 0.00 | (115.77) | (293.14) | 0.00 | (293.1) pt | ||||||
| ROE | — | 47.67 | 65.76 | (826.99) | 13.71 | (46.37) | (63.92) | (62.52) | (10.02) | (21.42) | 0.00 | (69.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 185 | 185 | 228 | 378 | 318 | 220 | 32 | 30 | — | (22.9%) | |||||
| Revenue/emp, $m | — | 0.00 | 0.04 | 0.02 | 1.04 | 0.04 | (0.10) | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2023 · fundamentals updated 26 Oct 2026
NovaBridge Biosciences vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HUMA Humacyte, Inc. | $109.9M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| NERV Minerva Neurosciences, Inc | $109.8M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OTLK Outlook Therapeutics, Inc. | $106.9M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| VYGR Voyager Therapeutics, Inc. | $106.0M | — (loss-making) | — (loss-making) | −69.97% (below 0%: shrinking) | n/m | +37.08% (above 0%: growing) | 100.00% | (658.25%) | Compare |
| NBP NovaBridge Biosciences | $105.3M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | |
| ANIX ANIXA BIOSCIENCES INC | $105.3M | — (loss-making) | — (loss-making) | 0.00% | n/m | −17.14% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $102.9M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| HURA TuHURA Biosciences, Inc. | $102.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OKUR OnKure Therapeutics, Inc. | $102.3M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $105.7M | — | — | −34.98% | — | +0.35% | 0.00% | 0.00% |